Insights into tuberculosis: A survival analysis of time to recurrence in Portugal, between 2002 and 2009. by Soares, P et al.
Insights into tuberculosis: a survival analysis of time to recurrence in Portugal, between 2002 and 2009

Patricia Soares1,2,3, Raquel Duarte 4,5,6, M. Gabriela M. Gomes 7,8, Cristina Rocha2,3, João Sollari Lopes1,9
1 Instituto Gulbenkian de Ciência, Oeiras, Portugal	
2 Departamento de Estatística e Investigação Operacional, Faculdade de Ciências, Universidade de Lisboa, 1749 – 016 Lisboa, Portugal 
3 Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa, 1749 – 016 Lisboa, Portugal
4 Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal
5 Faculdade de Medicina, Universidade do Porto, Porto, Portugal
6 EpiUnit, Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal
7 Liverpool School of Tropical Medicine, Liverpool, United Kingdom
8 CIBIO-InBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, and CMUP, Centro de Matemática da Universidade do Porto, Porto, Portugal
9 Instituto Nacional de Estatística, Lisboa, Portugal

Correspondence: 
Patricia Soares
E-mail: patseraos@gmail.com (​mailto:patseraos@gmail.com​)
Recurrence of TB has been associated with poor adherence to treatment, smoking, alcoholism, unemployment, drug abuse, the severity of pulmonary cavitations, HIV infection and duration of treatment 1. However, the risk factors can vary considerably across countries and between studies. Since little is known about risk factors for recurrence in Portugal, we aimed to identify predictors of treatment recurrence in the country. Surveillance data on TB for the period of 2002-2009 was provided by SVIG-TB, a database from the Portuguese National Health System. For this analysis, only cases of confirmed TB disease were considered, and patients with information on the first and second TB episodes. The variables studied were chosen according to previous reports as TB risk factors, particularly regarding TB recurrence. The existence of missing data was assessed and characterised regarding missing data (missingness between 0 and 10%). From this characterization, we chose to perform multiple imputation using a random-forest based on multivariate imputation by chained equations. We used a semi-parametric Cox regression model in which the event of interest was the second episode of TB, with time being measured since the end of treatment for a first TB episode. Patients without the second episode of TB before the end of the study were censored. A total of 8364 individuals were analysed, of which 145 (1.73%) had a recurrent TB episode during the time of the study. 
Patients that defaulted TB treatment are ten times more likely to suffer a recurrent case of TB (Table 1). As expected 1, HIV was positively associated with recurrence of TB disease (Table 1). Alcohol use disorders have been associated with recurrent TB, mostly by linkage to other confounding factors1,2. We found that even when considering treatment default, TB patients with an alcohol use disorder still had a significant 86% increase in the risk of recurring with TB (Table 1). Being incarcerated is a known risk factor for TB mainly due to overcrowding, delayed diagnosis and/or inadequate treatment. Our study shows that in Portugal, the risk of TB recurrence for prison inmates is four times higher (Table 1). The standard 6-month treatment regimen is often insufficient to prevent TB relapse 3, nevertheless, the study of treatment length as a risk factor has been mostly restricted to TB patients living with HIV 4. Longer treatments are usually prescribed to patients with poor prognostic, potentially confounding a beneficial effect. We found a decrease of 10% in the risk of recurrence per added month while accounting for the effect of other risk factors (e.g. HIV), which may suggest a need to reevaluate standard treatment regimens (Table 1). The inclusion of the clinical form in a study about recurrence is unusual. Most studies discard extrapulmonary TB cases since this form is much less infectious, contributing less to overall TB epidemics 1. Nevertheless, we found that there is a two times increase in the risk of recurrence when suffering from an extrapulmonary form of the disease (table 1). Driver et al. 4 showed that in TB patients living with HIV, extrapulmonary disease increased the risk of suffering a recurrence, and Millet et al. 2 suggested that this was true irrespective of HIV status. Interestingly, some TB risk factors have been shown to be associated with the clinical form – i.e. having HIV or young age increases the chance of having an extrapulmonary infection, while smoking and living with diabetes increases the chance of a pulmonary TB. Regardless of the association between young age and extrapulmonary TB, the role of age in TB recurrence is somewhat uncertain, with some studies 5 indicating a decrease of risk for older people while others 6 suggest a reduction for younger individuals. In Portugal, we found that an increase of one year in the age of the patient leads to a decrease of 1% in the risk of a recurrent episode (Table 1). The association between diabetes and TB incidence has been relatively established, but the association with TB recurrence is unclear 3. Although the variable is not significant, we have estimated a decrease of 80% in the risk of a recurrent episode when having diabetes (Table 1). In this study, 55% of recurrence occurred in the first 12 months since treatment completion suggesting that in Portugal most of TB recurrence cases were due to relapse since relapse occurs not long after the end of treatment 7. Nevertheless, future studies should consider the inclusion of mycobacterial DNA information to distinguish between relapse and exogenous reinfection. 
To the best of our knowledge, this is the only study to date regarding risk factors for TB recurrence in Portugal. The study concerns the period 2002-2009 and, although the situation may have changed over the last decade, this cannot be assessed unless datasets linking multiple disease episodes at the individual level are made available to researchers. Understanding risk factors for TB recurrence in Portugal can help to define new guidelines to reduce the prevalence of recurrence, decreasing the chance of development of multi-drug resistant TB. 
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TABLES
Table 1 - Hazard ratios and 95% confidence intervals for TB recurrence.
Variables	β (se)	HR	CI (95%)	p-value
Treatment outcome	2.32 (0.197)	10.18	[6.90, 14.93]	<0.001
Prison	1.31 (0.522)	3.63	[1.41, 10.81]	0.012
HIV	0.85 (0.202)	2.34	[1.58, 3.48]	<0.001
Clinical Form	0.77 (0.235)	2.14	[1.35, 3.40]	0.001
Alcohol	0.62 (0.195)	1.86	[1.26, 2.74]	0.002
Age	-0.01 (0.006)	0.99	[0.98, 0.99]	0.033
Length of treatment	-0.12 (0.021)	0.90	[0.86, 0.93]	<0.001
Diabetes	-1.61 (1.007)	0.20	[0.03, 1.44]	0.110
se, standard error; HR, hazard ratio; CI, confidence interval.
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